Bear Robotics Bets on Elevator Interoperability With a Strategic Investment in M2MTech
19.4.2023 15:57:00 EEST | Business Wire | Press release
Bear Robotics, a Silicon Valley-based innovator of indoor service robots, is continuing its advancements in the robotics and artificial intelligence space. The tech pioneers just announced a strategic investment to fund its Korea-based partner, M2MTech, which specializes in IoT convergence for smart remote and predictive systems with elevators.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005038/en/
Servi Lift provides a reliable delivery experience with its elevator integration, making deliveries in multi-story buildings a breeze. (Photo: Business Wire)
This investment comes as Bear Robotics now extends their world-renowned Servi robot line with a fully integrated elevator delivery robot, Servi Lift, which is capable of completing last-mile deliveries inside of multi-story buildings such as hotels, senior living communities, ghost kitchens, hospitals, corporate campuses, and other high-rise commercial and residential real estate properties. "We believe this investment will truly maximize facility efficiencies and minimize user inconvenience,” commented John Ha, co-founder and Chief Executive Officer of Bear Robotics. “The ELSA convergence platform developed by M2MTech provides strong security, interoperability, and connectivity advantages that will set the stage for us to scale our last-mile mobility solutions.”
In engineering Servi Lift, Bear Robotics sought interoperability as its absolute competitive advantage to be applied with major players in the smart elevator market such as OTIS, TKE, Mitsubishi, KONE, Hyundai and Schindler. With the expansion of urbanization, Bear Robotics is bullish on the “smart city” shift to robot-friendly buildings, enhanced access security, and the penetration of smart elevators in smart buildings with strong linkages between systems. “With the global IoT elevator market forecasted to grow to $64 billion by 2030, it was imperative for us to invest into our close partnership with M2MTech that our engineering teams have built over the last couple of years, and to realize the synergies we believe will advance our last-mile aspirations,” commented Juan Higueros, co-founder and Chief Operating Officer of Bear Robotics. “We are confident that this collaborative approach will generate more efficient operations for many of our existing customers and open a broad array of new opportunities that will place Bear Robotics in a position to be the world’s leading multi-story robot delivery solutions provider.”
100 trials of Servi Lift are reserved for 2023. Broader rollouts are lined up across the world in 2024.
About Bear Robotics
Founded in 2017, Bear Robotics manufactures self-driving indoor robots to assist employees on daily tasks that can ease their workload. The Company’s flagship Servi robots have been deployed in hospitality, healthcare, retail, and real estate venues in North America, Europe, and Asia. For additional information, please visit www.bearrobotics.ai.
About M2MTech
Founded in 2014, M2MTech has developed an open and interoperable platform named ELSA (Elevator Smart Advisor, Elevator Smart Remote Management, Smart Predictive Maintenance System). For additional information, please visit https://m2mtech.co.kr/en/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005038/en/
Contact information
Alison Suzuki
Phone: 1-844-SAY-BEAR
Email:
press@bearrobotics.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom